ASH 2019 | ERd in the treatment of newly diagnosed MM

Jesús Berdeja

Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses a phase II study (NCT02843074) to assess the feasibility and tolerance of the combination of elotuzumab, lenalidomide and dexamethasone (ERd) in the induction, consolidation and maintenance treatment of patients with transplant-eligible newly diagnosed multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter